BiotechTube
Home/Atrogi/Philip Berglöf
PB

Philip Berglöf

CFO

Atrogi

Therapeutic Areas

Metabolic DisordersDiabetesMuscular WastingObesity

Atrogi Pipeline

DrugIndicationPhase
ATR-258Metabolic disorders (e.g., Type 2 Diabetes, Muscular Wasting)Phase 2

Leadership Team at Atrogi

PL
Paul Little
CEO
TB
Tore Bengtsson
Founder & CSO
AL
Anna-Maria Langkilde
CMO
SK
Sofia Karlström
Head of Chemistry and IP
ND
Nodi Dehvari
Head of Biology
ER
Erik Rollman Waara
COO
View full Atrogi profile